Mats Thorén

With over 25 years of experience in the financial markets, Mats Thorén has established himself as a prominent investor focusing on the healthcare and life sciences sectors. He founded Vixco Capital AB, a private investment firm, where he serves as CEO and board member. His investment portfolio includes companies such as Arcoma AB, Xbrane BioPharma AB, Herantis Pharma Oy, and FluoGuide A/S. Additionally, he has held board positions at C-RAD AB, Cellartis AB, and MIP Technologies AB. Thorén's expertise spans early-stage to late-stage investments, with a geographical focus on Sweden, Denmark, Finland, Norway, Germany, the United Kingdom, the United States, Canada, China, Japan, South Korea, India, Australia, Brazil, Mexico, South Africa, Russia, the United Arab Emirates, Saudi Arabia, Singapore, and South Africa. His industry interests encompass healthcare, life sciences, technology, medtech, biotech, pharmaceuticals, medical devices, diagnostics, digital health, e-commerce, fintech, edtech, cleantech, agtech, and foodtech. Thorén holds a degree in Economics from the Stockholm School of Economics and has studied medicine at the Karolinska Institute in Stockholm. His investment philosophy emphasizes strategic growth and innovation within the healthcare and life sciences sectors, aiming to support companies that drive advancements in medical technology and patient care. He is known for his hands-on approach, actively engaging with portfolio companies to foster development and achieve sustainable success. Thorén's extensive network and deep understanding of the industry enable him to identify and capitalize on emerging opportunities, contributing to the growth and success of the companies he invests in. His commitment to excellence and strategic vision have solidified his reputation as a leading investor in the healthcare and life sciences sectors.

Strong management team, Innovative product or service, Scalable business model, Clear path to profitability, Alignment with investment philosophy